{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:51:34Z","timestamp":1791827494050,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dysregulation of apoptosis is a key feature of acute myeloid leukemia (AML) and contributes to therapy resistance, yet the clinical relevance of apoptosis-related gene expression remains incompletely understood. We prospectively analyzed mRNA expression of apoptosis-related genes in bone marrow mononuclear cells from 90 newly diagnosed AML patients. Gene expression clustering identified two biologically distinct patient groups. The subgroup with significantly inferior overall survival (Cluster 2) showed coordinated upregulation of pro-apoptotic genes, including\n                    <jats:italic>BCL2L11 (BIM)<\/jats:italic>\n                    ,\n                    <jats:italic>BBC3 (PUMA)<\/jats:italic>\n                    ,\n                    <jats:italic>BID<\/jats:italic>\n                    ,\n                    <jats:italic>BAD<\/jats:italic>\n                    ,\n                    <jats:italic>BIK<\/jats:italic>\n                    , and\n                    <jats:italic>BAX<\/jats:italic>\n                    , together with a shift in anti-apoptotic signaling toward lower\n                    <jats:italic>BCL2<\/jats:italic>\n                    expression and increased expression of alternative survival regulators,\n                    <jats:italic>MCL1<\/jats:italic>\n                    and\n                    <jats:italic>BCL2L1 (BCL-xL)<\/jats:italic>\n                    . Reduced expression of executioner caspases\n                    <jats:italic>CASP3<\/jats:italic>\n                    and\n                    <jats:italic>CASP7<\/jats:italic>\n                    was also observed in Cluster 2, which may indicate less efficient apoptotic execution. Among patients treated with venetoclax\u2009+\u2009azacitidine (VenAza), Cluster 2 demonstrated significantly shorter event-free survival. This finding is consistent with the biological features of Cluster 2, including a monocytic immunophenotype previously associated with reduced sensitivity to BCL-2\u2013targeted therapy and increased reliance on alternative anti-apoptotic regulators such as MCL1 and BCL-xL. Analysis of individual genes showed that higher\n                    <jats:italic>BIK<\/jats:italic>\n                    mRNA expression was associated with poorer survival and lack of response to VenAza, highlighting the paradoxical association between increased expression of this pro-apoptotic gene and adverse clinical outcome. These findings demonstrate that dysregulation of apoptosis-related gene expression defines clinically distinct AML subgroups and may contribute to differences in prognosis and therapeutic response.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07268-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:56:25Z","timestamp":1789044985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-7963","authenticated-orcid":false,"given":"Kinga","family":"Strza\u0142ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Strza\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Jarych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Wi\u015bnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Mikulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Ko\u015bcielny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Czemerska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Zawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Pluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"2","key":"7268_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ (2023) The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica 108(2):308\u2013320. https:\/\/doi.org\/10.3324\/haematol.2022.280801","journal-title":"Haematologica"},{"key":"7268_CR2","doi-asserted-by":"publisher","unstructured":"Krawiec K, Strza\u0142ka P, Czemerska M et al (2022) Targeting Apoptosis in AML: Where Do We Stand? Cancers (Basel). 14(20):4995. https:\/\/doi.org\/10.3390\/cancers14204995","DOI":"10.3390\/cancers14204995"},{"key":"7268_CR3","doi-asserted-by":"publisher","first-page":"116667","DOI":"10.1016\/j.biopha.2024.116667","volume":"175","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhou X (2024) Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential. Biomed Pharmacother 175:116667. https:\/\/doi.org\/10.1016\/j.biopha.2024.116667","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7268_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20(3):175\u2013193. https:\/\/doi.org\/10.1038\/s41580-018-0089-8","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7268_CR5","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A et al (2019) Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 104:e434\u2013e437. https:\/\/doi.org\/10.3324\/haematol.2019.222588","journal-title":"Haematologica"},{"key":"7268_CR6","doi-asserted-by":"publisher","first-page":"584974","DOI":"10.3389\/fonc.2020.584974","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei Y, Cao Y, Sun R et al (2020) Targeting Bcl-2 Proteins in Acute Myeloid Leukemia. Front Oncol 10:584974. https:\/\/doi.org\/10.3389\/fonc.2020.584974","journal-title":"Front Oncol"},{"issue":"12","key":"7268_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"1","key":"7268_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12859-020-03743-8","volume":"21","author":"S Grabia","year":"2020","unstructured":"Grabia S, Smyczynska U, Pagacz K et al (2020) NormiRazor: tool applying GPU-accelerated computing for determination of internal references in microRNA transcription studies. BMC Bioinformatics 21(1):425. https:\/\/doi.org\/10.1186\/s12859-020-03743-8","journal-title":"BMC Bioinformatics"},{"issue":"1\u20132","key":"7268_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","volume":"28","author":"D Kaloni","year":"2023","unstructured":"Kaloni D, Diepstraten ST, Strasser A et al (2023) BCL-2 protein family: attractive targets for cancer therapy. Apoptosis 28(1\u20132):20\u201338. https:\/\/doi.org\/10.1007\/s10495-022-01780-7","journal-title":"Apoptosis"},{"issue":"13","key":"7268_CR10","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/cancers13133175","volume":"13","author":"L Handschuh","year":"2021","unstructured":"Handschuh L, Wojciechowski P, Kazmierczak M et al (2021) Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia. Cancers (Basel) 13(13):3175. https:\/\/doi.org\/10.3390\/cancers13133175","journal-title":"Cancers (Basel)"},{"key":"7268_CR11","doi-asserted-by":"publisher","unstructured":"Mamdouh AM, Olesinski EA, Lim FQ et al TP53 mutations drive therapy resistance via post-mitochondrial caspase blockade. bioRxiv [Preprint]. 2025 Aug 31:2025.08.28.672283. https:\/\/doi.org\/10.1101\/2025.08.28.672283","DOI":"10.1101\/2025.08.28.672283"},{"issue":"7","key":"7268_CR12","doi-asserted-by":"publisher","first-page":"eaau9433","DOI":"10.1126\/sciadv.aau9433","volume":"5","author":"S McComb","year":"2019","unstructured":"McComb S, Chan PK, Guinot A et al (2019) Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7. Sci Adv 5(7):eaau9433. https:\/\/doi.org\/10.1126\/sciadv.aau9433","journal-title":"Sci Adv"},{"issue":"47","key":"7268_CR13","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1038\/s41388-025-03616-5","volume":"44","author":"G Twito","year":"2025","unstructured":"Twito G, Abu Abayed FA, Gilad A et al (2025) Correction: Non-genetic inactivation of caspase-3 and P53 increases cancer cell fitness by PDIA4 redistribution. Oncogene 44(47):4671. https:\/\/doi.org\/10.1038\/s41388-025-03616-5. Erratum for: Oncogene. 2025;44(47):4565\u20134575. doi: 10.1038\/s41388-025-03606-7","journal-title":"Oncogene"},{"key":"7268_CR14","doi-asserted-by":"publisher","first-page":"738301","DOI":"10.1155\/2011\/738301","volume":"2011","author":"Y Lu","year":"2011","unstructured":"Lu Y, Chen GQ (2011) Effector caspases and leukemia. Int J Cell Biol 2011:738301. https:\/\/doi.org\/10.1155\/2011\/738301","journal-title":"Int J Cell Biol"},{"issue":"6","key":"7268_CR15","doi-asserted-by":"publisher","first-page":"118688","DOI":"10.1016\/j.bbamcr.2020.118688","volume":"1867","author":"A Boice","year":"2020","unstructured":"Boice A, Bouchier-Hayes L (2020) Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res 1867(6):118688. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118688","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"7268_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcdb.2023.07.005","volume":"156","author":"G Sun","year":"2024","unstructured":"Sun G (2024) Death and survival from executioner caspase activation. Semin Cell Dev Biol 156:66\u201373. https:\/\/doi.org\/10.1016\/j.semcdb.2023.07.005","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"7268_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3324\/haematol.2021.280201","volume":"107","author":"I Ferrarini","year":"2022","unstructured":"Ferrarini I, Rigo A, Visco C (2022) The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine. Haematologica 107(4):790\u2013802. https:\/\/doi.org\/10.3324\/haematol.2021.280201","journal-title":"Haematologica"},{"issue":"6","key":"7268_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 AM, Renders S et al (2023) Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax. Cancer Discov 13(6):1408\u20131427. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0939","journal-title":"Cancer Discov"},{"key":"7268_CR19","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH et al (2023) Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev 59:101036. https:\/\/doi.org\/10.1016\/j.blre.2022.101036","journal-title":"Blood Rev"},{"issue":"4","key":"7268_CR20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2024) Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 99(4):615\u2013624. https:\/\/doi.org\/10.1002\/ajh.27246","journal-title":"Am J Hematol"},{"issue":"5","key":"7268_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/2643-3230.BCD-24-0256","volume":"6","author":"CA Lachowiez","year":"2025","unstructured":"Lachowiez CA, Heiblig M, Aspas Requena G et al (2025) Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study. Blood Cancer Discov 6(5):437\u2013449. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0256","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"7268_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ajh.70161","volume":"101","author":"M Konopleva","year":"2026","unstructured":"Konopleva M, DiNardo CD, Sun Y et al (2026) Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. Am J Hematol 101(3):577\u2013580. https:\/\/doi.org\/10.1002\/ajh.70161","journal-title":"Am J Hematol"},{"issue":"11","key":"7268_CR23","first-page":"5300","volume":"12","author":"P Liu","year":"2022","unstructured":"Liu P, Jiao F, Zhang Z et al (2022) Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations. Am J Cancer Res 12(11):5300\u20135314","journal-title":"Am J Cancer Res"},{"issue":"6","key":"7268_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41419-020-2654-2","volume":"11","author":"V Pandya","year":"2020","unstructured":"Pandya V, Githaka JM, Patel N et al (2020) BIK drives an aggressive breast cancer phenotype through sublethal apoptosis and predicts poor prognosis of ER-positive breast cancer. Cell Death Dis 11(6):448. https:\/\/doi.org\/10.1038\/s41419-020-2654-2","journal-title":"Cell Death Dis"},{"key":"7268_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41231-024-00181-z","volume":"9","author":"A\u2013EA Taha","year":"2024","unstructured":"Taha A\u2013EA, Omar S, Abdelsattar NK et al (2024) Primed for death: prognostic role of BH3\u2013only proteins in breast cancer therapy: a systematic and meta\u2013analysis review. Transl Med Commun 9:24. https:\/\/doi.org\/10.1186\/s41231-024-00181-z","journal-title":"Transl Med Commun"},{"issue":"12","key":"7268_CR26","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1371\/journal.pmed.0030467","volume":"3","author":"Y Lu","year":"2006","unstructured":"Lu Y, Lemon W, Liu PY et al (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3(12):e467. https:\/\/doi.org\/10.1371\/journal.pmed.0030467","journal-title":"PLoS Med"},{"issue":"Suppl 1","key":"7268_CR27","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/onc.2009.40","volume":"27","author":"G Chinnadurai","year":"2008","unstructured":"Chinnadurai G, Vijayalingam S, Rashmi R (2008) BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene 27(Suppl 1):S20\u2013S29. https:\/\/doi.org\/10.1038\/onc.2009.40","journal-title":"Oncogene"},{"issue":"22","key":"7268_CR28","doi-asserted-by":"publisher","first-page":"33272","DOI":"10.18632\/oncotarget.8924","volume":"7","author":"V Pandya","year":"2016","unstructured":"Pandya V, Glubrecht D, Vos L et al (2016) The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer. Oncotarget 7(22):33272\u201333285. https:\/\/doi.org\/10.18632\/oncotarget.8924","journal-title":"Oncotarget"},{"issue":"1","key":"7268_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12943-024-02145-1","volume":"23","author":"S Li","year":"2024","unstructured":"Li S, Lv J, Li Z et al (2024) Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT\/BCL2\/BECN1 pathway. Mol Cancer 23(1):243. https:\/\/doi.org\/10.1186\/s12943-024-02145-1","journal-title":"Mol Cancer"},{"issue":"2","key":"7268_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/med.21379","volume":"36","author":"Z Liu","year":"2016","unstructured":"Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J (2016) Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev 36(2):313\u2013341. https:\/\/doi.org\/10.1002\/med.21379","journal-title":"Med Res Rev"},{"issue":"2","key":"7268_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2(2):183\u2013192. https:\/\/doi.org\/10.1016\/S1535-6108(02)00127-7","journal-title":"Cancer Cell"},{"issue":"16","key":"7268_CR32","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","volume":"24","author":"LV Pham","year":"2018","unstructured":"Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M (2018) Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res 24(16):3967\u20133980. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3004","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"7268_CR33","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1182\/blood-2023-187756","volume":"142","author":"P Strza\u0142ka","year":"2023","unstructured":"Strza\u0142ka P, Krawiec K, Jarych D et al (2023) Assessment of SIRT1\u2013SIRT7 and TP53 Genes Expression in Patients with Acute Myeloid Leukemia. Blood 142(Suppl 1):6048. https:\/\/doi.org\/10.1182\/blood-2023-187756","journal-title":"Blood"},{"key":"7268_CR34","doi-asserted-by":"publisher","first-page":"e1178","DOI":"10.32113\/wcrj_201812_1178","volume":"5","author":"A Ahmadzadeh","year":"2018","unstructured":"Ahmadzadeh A, Mohammadi MH, Mezginezhad F et al (2018) The expression of the TP53 gene in various classes of acute myeloid leukemia. World Cancer Res J 5:e1178. https:\/\/doi.org\/10.32113\/wcrj_201812_1178","journal-title":"World Cancer Res J"},{"issue":"6","key":"7268_CR35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/cancers17061009","volume":"17","author":"P Strza\u0142ka","year":"2025","unstructured":"Strza\u0142ka P, Krawiec K, Wi\u015bnik A et al (2025) The Role of the Sirtuin Family Histone Deacetylases in Acute Myeloid Leukemia-A Promising Road Ahead. Cancers (Basel) 17(6):1009. https:\/\/doi.org\/10.3390\/cancers17061009","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7268_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3892\/ol.2019.11064","volume":"19","author":"W Weng","year":"2020","unstructured":"Weng W, Zhang P, Ruan J et al (2020) Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia. Oncol Lett 19(1):549\u2013556. https:\/\/doi.org\/10.3892\/ol.2019.11064","journal-title":"Oncol Lett"},{"key":"7268_CR37","doi-asserted-by":"publisher","first-page":"3801526","DOI":"10.1155\/2023\/3801526","volume":"2023","author":"Y Jin","year":"2023","unstructured":"Jin Y, Zhao X, Song X et al (2023) The High Expression of p53 Is Predictive of Poor Survival Rather TP53 Mutation in Esophageal Squamous Cell Carcinoma. J Oncol 2023:3801526. https:\/\/doi.org\/10.1155\/2023\/3801526","journal-title":"J Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07268-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07268-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:29:55Z","timestamp":1791826195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07268-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7268"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07268-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Bioethics Committee of the Medical University of Lodz, Poland (approval no. RNN\/207\/21\/KE, July 13, 2021). All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"452"}}